{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:25:18Z","timestamp":1782840318593,"version":"3.54.5"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Clearside Biomedical, Alpharetta, GA"},{"name":"Bausch + Lomb, Bridgewater, NJ"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To develop professional guidelines for best practices for suprachoroidal space (SCS) injection, an innovative technique for retinal therapeutic delivery, based on current published evidence and clinical experience.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A panel of expert ophthalmologists reviewed current published evidence and clinical experience during a live working group meeting to define points of consensus and key clinical considerations to inform the development of guidelines for in-office SCS injection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Core consensus guidelines for in-office SCS injection were reached and reported by the expert panel. Current clinical evidence and physician experience supported SCS injection as a safe and effective method for delivering retinal and choroidal therapeutics. The panel established consensus on the rationale for SCS injection, including potential benefits relative to other intraocular delivery methods and current best practices in patient preparation, pre- and peri-injection management, SCS-specific injection techniques, and postinjection management and follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>These expert panel guidelines may support and promote standardization of SCS injection technique, with the goal of optimizing patient safety and outcomes. Some aspects of the procedure may reasonably be modified based on the clinical setting and physician judgment, as well as additional study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004087","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T22:01:38Z","timestamp":1709762498000},"page":"939-949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["SUPRACHOROIDAL SPACE INJECTION TECHNIQUE"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"first","affiliation":[{"name":"Retinal Consultants of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Avery","sequence":"additional","affiliation":[{"name":"California Retina Consultants, Santa Barbara, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[{"name":"Retinal Consultants of Arizona, Phoenix, Arizona;"},{"name":"University of Arizona College of Medicine \u2013 Phoenix, Phoenix, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[{"name":"Retina-Vitreous Associates Medical Group, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Retinal Consultants of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Brucker","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmett T.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, California Pacific Medical Center, San Francisco, California;"},{"name":"The Francis I Proctor Foundation, UCSF School of Medicine, San Francisco, California;"},{"name":"Department of Ophthalmology, Stanford University School of Medicine, Stanford, California;"},{"name":"West Coast Retina Medical Group, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Heier","sequence":"additional","affiliation":[{"name":"Ophthalmic Consultants of Boston, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Holekamp","sequence":"additional","affiliation":[{"name":"Pepose Vision Institute, St. Louis, Missouri;"},{"name":"Roche Pharmaceuticals, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, Nevada;"},{"name":"University of Nevada, Reno School of Medicine, Reno, Nevada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Demirci","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[{"name":"Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Yiu","sequence":"additional","affiliation":[{"name":"University of California, Davis Health, Sacramento, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Chief Medical Advisor and Chair of Scientific Advisory Board, Clearside Biomedical, Alpharetta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jconrel.2022.05.061","article-title":"Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions","volume":"349","author":"Kansara","year":"2022","journal-title":"J Control Release"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Naftali Ben Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/OPTH.S89784","article-title":"The suprachoroidal space: from potential space to a space with potential","volume":"10","author":"Moisseiev","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.drudis.2014.10.010","article-title":"The suprachoroidal pathway: a new drug delivery route to the back of the eye","volume":"20","author":"Rai","year":"2015","journal-title":"Drug Discov Today"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"e17140","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS One"},{"key":"R10-20250605","article-title":"The hands-on technique for suprachoroidal injection","author":"Barakat","year":"2019","journal-title":"Retina Specialist"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.37765\/ajmc.2022.89270","article-title":"Microinjection via the suprachoroidal space: a review of a novel mode of administration","volume":"28","author":"Ciulla","year":"2022","journal-title":"Am J Manag Care"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"key":"R13-20250605","first-page":"233","article-title":"Hydrostatic pressure of the suprachoroidal space","volume":"30","author":"Emi","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ajo.2017.11.020","article-title":"Choroidal changes after suprachoroidal injection of triamcinolone acetonide in eyes with macular edema secondary to retinal vein occlusion","volume":"186","author":"Willoughby","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3928\/23258160-20180831-07","article-title":"Suprachoroidal space alterations following delivery of triamcinolone acetonide: post-hoc analysis of the phase 1\/2 HULK study of patients with diabetic macular edema","volume":"49","author":"Lampen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/aja.1001720403","article-title":"Restriction to endogenous plasma proteins by a fenestrated capillary endothelium: an ultrastructural immunocytochemical study of the choriocapillary endothelium","volume":"172","author":"Pino","year":"1985","journal-title":"Am J Anat"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J Angiogenes Res"},{"key":"R19-20250605","first-page":"5259","article-title":"Intraocular distribution and targeting of triamcinolone acetonide suspension administered into the supreachroidal space","volume":"55","author":"Edelhauser","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/tvst.10.7.19","article-title":"Evaluation of long-lasting potential of suprachoroidal axitinib suspension via ocular and systemic disposition in rabbits","volume":"10","author":"Kansara","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"R21-20250605","first-page":"459","article-title":"Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina","volume":"38","author":"Muya","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s40265-022-01777-1","article-title":"Suprachoroidal space triamcinolone acetonide: a review in uveitic macular edema","volume":"82","author":"Fung","year":"2022","journal-title":"Drugs"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","article-title":"Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)","volume":"106","author":"Henry","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R24-20250605","first-page":"1139","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","article-title":"Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space","volume":"352","author":"Jung","year":"2022","journal-title":"J Control Release"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"119935","DOI":"10.1016\/j.biomaterials.2020.119935","article-title":"Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization","volume":"243","author":"Hackett","year":"2020","journal-title":"Biomaterials"},{"key":"R29-20250605","first-page":"1209","article-title":"Safety of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders","volume":"62","author":"Sharma","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-20250605","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.9.11.27","article-title":"Clinical characterization of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders","volume":"9","author":"Wan","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"R37-20250605","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Intravitreal injection technique and monitoring: updated guidelines of an expert panel","volume":"34","author":"Avery","year":"2014","journal-title":"Retina"},{"key":"R38-20250605","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.exer.2009.11.001","article-title":"Dimensions of the human sclera: thickness measurement and regional changes with axial length","volume":"90","author":"Norman","year":"2010","journal-title":"Exp Eye Res"},{"key":"R39-20250605","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/09273948.2021.1954199","article-title":"Suprachoroidal CLS-TA with and without systemic corticosteroid and\/or steroid-sparing therapy: a post-hoc analysis of the phase 3 PEACHTREE clinical trial","volume":"31","author":"Merrill","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R40-20250605","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ceo.14024","article-title":"Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: a post hoc analysis of PEACHTREE","volume":"50","author":"Singer","year":"2022","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:02:58Z","timestamp":1749142978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004087"}},"subtitle":["Expert Panel Guidance"],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004087","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}